<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SII-45116</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Pharma Indonesia</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Brightgene Bio-Medical Technology Co., Ltd. (Brightgene or the Company) is a leading Chinese
pharmaceutical company that focuses on the research and manufacturing of high barrier generics, active
pharmaceutical ingredients (APIs), and finished dosage forms (FDFs). The proposed IFC investment will
support Brightgenes expansion into Indonesia to meet the growing local demand in the country (the Project)</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">Project level: The Project is expected to benefit patients in Indonesia through increase in the local production of quality pharmaceutical products. It is expected to make the health system more resilient to supply chain shocks of the kind that affected countries during the pandemic. The Project is also expected to benefit employees through the creation of local jobs along with skill training opportunities.  
Market level: The Project is expected to increase the competitiveness and resilience of the pharmaceutical markets in Indonesia. By supporting the introduction of relatively sophisticated production and the creation of a pool of well-trained workers with hands-on experience, the Project will lay the basis for further development of the pharmaceutical sector in Indonesia.</narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SII-45116" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="1"></activity-status>
  <activity-date iso-date="2022-06-27" type="1"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">0  0  0  0  0  0  0  0  0.0000         &#xA0;  Karawang   New Industry City, Block B No. 8 Jl. Trans   Heksa   Km.7,   Karawang  , West Java, 41361, Indonesia</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">PT Brightgene Biomedical Indonesia  Mr. Robert Ellerson  Director  +62 821-38582010  Robert.ellerson@ptbrightgene.com  Karawang New Industry City, Block B No. 8 Jl. Trans Heksa Km.7, Karawang, West Java, 41361, Indonesia  www.bright-gene.com</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="ID" percentage="100">
   <narrative xml:lang="EN">Indonesia</narrative>
  </recipient-country>
  <location ref="ID-Indonesia">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">Karawang New Industrial City, West Java Province, Indonesia</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>-5.0000000000 120.0000000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">other</narrative>
  </sector>
  <country-budget-items vocabulary="1">
   <budget-item code="7.2.1" percentage="100" vocabulary="1">
    <description>
     <narrative xml:lang="EN">Total: $50.00 million</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-finance-type code="411"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget type="1">
   <period-start iso-date="2022-06-27"></period-start>
   <period-end iso-date="2022-06-30"></period-end>
   <value currency="USD" value-date="2022-06-27">50000000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2022-06-27"></transaction-date>
   <value currency="USD" value-date="2022-06-27">50000000</value>
   <receiver-org>
    <narrative xml:lang="EN">BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.</narrative>
   </receiver-org>
   <flow-type code="35"></flow-type>
   <finance-type code="411"></finance-type>
  </transaction>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/project-detail/SII/45116/pharma-indonesia">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information - Anticipated Impact Measurement &amp; Monitoring (AIMM) Assessment and Main Environmental &amp; Social Risks and Impacts of the Project</narrative>
   </title>
   <category code="A01"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/project-detail/SII/45116/pharma-indonesia">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
 </iati-activity>
</iati-activities>
